The abstract reports Wernicke's encephalopathy as a rare but serious neurological adverse event requiring thiamine monitoring, but provides no mechanistic explanation for how fedratinib disrupts thiamine metabolism or utilization. Understanding this mechanism is critical for preventing this potentially fatal neurological complication. Gap type: unexplained_observation Source paper: Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis. (2021, Leukemia, PMID:32647323)
Landscape Summary: What is the mechanism by which fedratinib causes Wernicke's encephalopathy in ~1% of patients? is a 0.8 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: open.
Colonna, Sevlever, et al. (TREM2 biology)
What is the mechanism by which fedratinib causes Wernicke's encephalopathy in ~1% of patients? — INVOKE-2 (completed)
No hypotheses linked to this gap yet.
No knowledge graph edges recorded
No activity recorded yet.
No discussions yet. Be the first to comment.
Create sub-tasks to investigate specific aspects of this gap: